Ratings UnitedHealth Group Incorporated Sao Paulo

Equities

UNHH34

BRUNHHBDR000

Delayed Sao Paulo Other stock markets 03:53:14 2024-05-21 pm EDT			5-day change	1st Jan Change
38.3 ^BRL	+0.84%		+1.70%	+5.83%

02:28pm	Utah Continued to Face Issues After UnitedHealth Claimed Progress With Hack Repairs	MT
May. 20	UnitedHealth's unit to launch new drug pricing model next year	RE

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Analyst opinion has improved significantly over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
With a 2024 P/E ratio at 28.88 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
UNITEDHEALTH GROUP INCORPORATED	+5.83%	482B	-
ELEVANCE HEALTH, INC.	+16.02%	127B	A-
CIGNA	+12.18%	95.56B	B-
HUMANA INC.	-22.30%	42.85B	A-
CENTENE CORPORATION	+6.19%	41.84B	B-
MOLINA HEALTHCARE, INC.	-4.97%	20.06B	B-
PROGYNY, INC.	-27.00%	2.61B	C+
ALIGNMENT HEALTHCARE, INC.	-11.67%	1.42B	B-
CLOVER HEALTH INVESTMENTS, CORP.	-1.44%	460M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes